Incretin Atlas › Trials › Phase 2b CTR20232069 (vs semaglutide)
Phase 2b CTR20232069 (vs semaglutide)
Bofanglutide (GZR18) · t2d
Design
- Molecule(s)
- Bofanglutide (GZR18)
- Population
- t2d
- Phase
- 2
- Participants
- 264
- Duration
- 24 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6 | t2d china | 24 | 264 | — | — | −1.9 | — | — | — | — | — | — | press release |
| 18 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6 | t2d china | 24 | 264 | — | — | −2.3 | — | — | — | — | — | — | press release |
| 24 mg Q2W vs semaglutide 1 mg QW (active comparator): HbA1c -1.6 | t2d china | 24 | 264 | — | — | −1.9 | — | — | — | — | — | — | press release |
| 24 mg QW vs semaglutide 1 mg QW (active comparator): HbA1c -1.6 | t2d china | 24 | 264 | — | — | −2.3 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (4)
- 12 mg Q2W · hba1c · press release
1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
- 18 mg Q2W · hba1c · press release
1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
- 24 mg Q2W · hba1c · press release
1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
- 24 mg QW · hba1c · press release
1.87% (12 mg, bi-weekly), 2.28% (18 mg, bi-weekly), 1.94% (24 mg, bi-weekly), and 2.32% (24 mg, once-weekly), all higher than the semaglutide group (1.60% reduction)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: Phase 2b CTR20232069 (vs semaglutide). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/phase-2b-ctr20232069/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.